Marius Pharmaceuticals Partners with Smartway to Design and Manage the global Early Access Program for KYZATREX™ (testosterone undecanoate)
10. August 2023 09:30 ET
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals (Marius) and Smartway Pharmaceuticals (Smartway) are pleased to announce their strategic partnership, aimed at addressing the...
Marius Pharmaceuticals Announces Launch of ReThink Testosterone, Disease-State Awareness Initiative for Patients
24. Juli 2023 09:00 ET
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., July 24, 2023 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a patient-centric healthcare company specializing in therapies for hypogonadism or Testosterone Deficiency, is proud to...
Marius Pharmaceuticals Supports AXYS 2023 Virtual Family Conference, Spotlighting KYZATREX™ for XY Chromosome Variations, such as Klinefelter’s Syndrome
20. Juni 2023 08:30 ET
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., June 20, 2023 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a patient-centric healthcare company specializing in therapies for hypogonadism or testosterone deficiency, announced today...
Marius Pharmaceuticals Announces Two Key Patents Related to KYZATREX™ in FDA Orange Book
09. Juni 2023 10:00 ET
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., June 09, 2023 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a patient-centric healthcare company focused on therapies designed for hypogonadism or testosterone deficiency, announced...
CORRECTION -- Marius Pharmaceuticals Receives FDA Approval of KYZATREX™, an Oral Testosterone Replacement Therapy
21. September 2022 11:08 ET
|
Marius Pharmaceuticals LLC
RALEIGH, N.C., Sept. 21, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline on August 2, 2022 by Marius Pharmaceuticals, please note that the correct number for reporting side...
Clarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering JATENZO® (testosterone undecanoate)
28. Juli 2022 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first and only FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., July ...
Global Testosterone Injectable Market to Grow with a CAGR of ~4% During 2022-2031; Market to Grow on the Back of the Increasing Prevalence of High-Risk Testosterone Deficiency, and Advancement in Healthcare Infrastructure
19. Juli 2022 07:35 ET
|
Research Nester
New York, July 19, 2022 (GLOBE NEWSWIRE) -- Hypogonadism is thought to affect 4 to 5 million men in the United States. Older men are particularly prone to have low testosterone levels. Free...
Clarus Therapeutics Announces Closing of Upsized $30.0 Million Underwritten Public Offering
27. April 2022 13:43 ET
|
Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill., April 27, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by...
Clarus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
30. März 2022 16:05 ET
|
Clarus Therapeutics Holdings, Inc.
2021 net revenue increased 119% year-over-year to $14.0 million Fourth quarter 2021 net revenue increased 88% year-over-year to $4.6 million Fourth quarter 2021 total prescription growth for...
Clarus Announces Initiation of Phase 4 Clinical Trial of JATENZO® (testosterone undecanoate) for the Treatment of Hypogonadal Men with Chronic Kidney Disease
16. März 2022 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first and only FDA-approved oral softgel for testosterone (T) replacement therapy in adult males who have deficient T due to certain medical conditions Clarus expects to announce...